FDA to Consider Drug With Suicide Risk

//FDA to Consider Drug With Suicide Risk

FDA to Consider Drug With Suicide Risk

FDA logo green background 240Mesh News Desk, July 15, 2016 ~ FDA will consider approving a drug that has some red flags for its association with a risk of suicide. 

The drug is made by Valeant and its called brodalumab.

Last May there were six suicides among the clinical trials. That prompted drugmaker Amgen to back out on its collaboration with AstraZeneca. The rights were then sold to Valeant.

It’s now up to an expert panel of the US Food and Drug Administration to decide whether brodalumab should be approved for sale.

The company admits there is limited data to assess the risk.

Brodalumab is a monoclonal antibody used to treat inflammatory diseases including psoriasis.

The FDA’s briefing documents are here.

Tuesday, July 19, the FDA panel of experts will meet. The FDA does not have to follow the recommendation of its experts, but usually does.

Read more on Fierce Pharma. ##

By | 2016-07-15T10:38:25+00:00 July 15th, 2016|Drugs Gone Wrong|0 Comments

About the Author:

I’m National News Editor, Jane Akre and I began Mesh Medical Device News Desk aka Mesh News Desk (MND) in the summer of 2011 just after the Food and Drug Administration issued an explicit warning to the public that complications associated with surgical mesh used for prolapse repair (POP) and incontinence (SUI) are NOT rare! That was the starting point for the litigation you see today and thousands of lawsuits have been filed by women whose lives have been altered, some permanently, by the use of this petroleum-based product.

Leave A Comment

Interested in our free Mesh webinar? Learn More
Webinar Starts